<DOC>
	<DOCNO>NCT00318838</DOCNO>
	<brief_summary>This study assess effect multiple dose 125 mg azimilide glomerular filtration rate ( GFR ) total creatinine clearance ( GFR + active secretion ) healthy subject . Also , assess effect multiple dose 125 mg azimilide renal hemodynamics ( RPF ) healthy subject .</brief_summary>
	<brief_title>Effect Azimilide Dihydrochloride Renal Function</brief_title>
	<detailed_description>This double-blind , parallel-group , placebo-controlled , multiple-dose , single-site study healthy male female volunteer . Oral azimilide 125 mg placebo administer every 12 hour 3 day , follow 125 mg every 24 hour 3 day . The study include total 21 healthy subject ( 14 active 7 placebo ) , confine study center 9 night .</detailed_description>
	<mesh_term>Azimilide</mesh_term>
	<criteria>Male hysterectomized postmenopausal ( last menstrual period &gt; 1 year ) female Between 18 45 year age , inclusive , screen In good general health base medical history , physical examination laboratory evaluation Body mass index 18 32 ( kg/m2 ) , inclusive Willing able fulfill requirement protocol provide write consent History diabetes , cardiovascular , hepatic , renal , gastrointestinal disease History use tobacco nicotinecontaining product within past 3 month Alcohol illicit drug abuse report habitual alcohol intake great 1.5 oz . ( ethanol equivalent ) per day ( e.g. , 24 ozs . beer , 10 ozs . wine , 3 ozs . hard liquor ) within past 2 year . History clinically significant ( opinion investigator ) allergic reaction drug multiple food/drug , contrast medium agent , PAH , iodine shell fish . Clinically significant abnormality upon physical examination , investigator 's opinion , would interfere conduct study Corrected QTinterval ( QTc ) &gt; 440 msec ( QT interval correct heart rate use Bazett 's formula ) . Clinically significant abnormality screen 12lead electrocardiogram ( ECG ) ; presence discernable U wave ( investigator 's opinion ) would interfere accurate measurement QT baseline and/or treatment . Personal family history long QT syndrome Absolute neutrophil count &lt; 1500/mm3 Potassium magnesium value ( ) outside laboratory normal range Any laboratory value ( ) outside laboratory normal range consider clinically significant investigator ( serum chemistry , hematology , coagulation , urinalysis . Serology positive hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) screen . If female , positive urine serum pregnancy test Positive urine screen drug abuse Reported use prescription drug herbal preparation within 14 day prior dose nonprescription drug vitamin within 7 day prior dose . Reported use know enzymeinducer , enzymeinhibitor , investigational drug within 30 day prior dose , report chronic exposure enzymeinducers paint solvent pesticide within 30 day dose . Blood donation approximately 400 mL within 4 week plasma donation 200 mL within 2 week prior dose . Acute illness within 2 week prior dose History presence , upon clinical evaluation , illness might impact safety test product administration evaluability drug effect base investigator 's discretion . Has participate another investigational drug study protocol within 30 day admission .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>